Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

Nele Claes¹, Tessa Dhaeze¹, Judith Fraussen¹, Bieke Broux¹, Bart Van Wijmeersch¹,², Piet Stinissen¹, Raymond Hupperts³,⁴, Niels Hellings¹, Veerle Somers¹*

¹ Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium, ² Rehabilitation & MS-Center, Overpelt, Belgium, ³ Department of Neuroscience, School of Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands, ⁴ Department of Neurology, Orbis Medical Center, Sittard, The Netherlands

Abstract

Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study.

Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naïve (n = 47) and interferon-treated (n = 27) MS patients.

Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p<0.001), both implicated in MS pathogenesis, while the proportion of naive B cells was increased during fingolimod treatment in the peripheral blood (PB) of MS patients (p<0.05). The remaining T cell population, in contrast, showed elevated proportions of memory conventional and regulatory T cells (p<0.01) and declined proportions of naive conventional and regulatory cells (p<0.05). These naive T cell subtypes are main drivers of MS pathogenesis. B cell expression of CD80 and CD86 and programmed death (PD)-1 expression on circulating follicular helper T cells was increased during fingolimod follow-up (p<0.05) pointing to a potentially compensatory mechanism of the remaining circulating lymphocyte subtypes that could provide additional help during normal immune responses.

Conclusions: MS patients treated with fingolimod showed a change in PB lymphocyte subtype proportions and expression of functional molecules on T and B cells, suggesting an association with the therapeutic efficacy of fingolimod.

Introduction

A complex interplay between T and B cells drives the disease course of multiple sclerosis (MS). Thereby, non class-switched (CD19+IgD+CD27-) and class-switched (CD19+IgD-CD27+) memory B cells are generally considered to be the main pathogenic B cell subtypes, whereas, conventional (autoreactive) T cells (CD4+CD25+CD127-) can drive the disease and regulatory T cells (CD4+CD25hiCD127lo) control immune homeostasis [1–5]. Both within the conventional and regulatory T cell populations, naive (CD45RA+CD45RO-) and memory (CD45RA-CD45RO+) subtypes can be discriminated. The role of other peripheral blood (PB) immune cells in MS pathogenesis, such as naïve B cells (CD19+IgD+CD27+), double negative B cells (CD19+IgD-CD27-)
and follicular helper T cells (TFH; CD4+CD25+CD127+ CXCR5+PD-1+), is still unclear. B and T cells interact via surface molecules e.g. human leukocyte antigen (HLA-DR/DP/DQ), CD80 and CD86 on B cells and programmed death (PD)-1 on T cells. Furthermore, migration of B and T cells is partly mediated via chemokine (C-X-C motif) receptor 5 (CXCR5) [4].

Fingolimod is the FDA approved oral treatment for MS and has shown efficacy in relapsing remitting (RR) MS [5-8]. Fingolimod is an immunomodulator that interferes with the signaling of the sphingosine-1-phospate receptor 1 (S1PR1), present on lymphocytes, and causes the internalization and degradation of this receptor [9]. Consequently lymphocytes cannot exit the lymph nodes into the circulation, leading to the entrapment of lymphocytes in lymphatic systems, causing lymphopenia in peripheral blood (PB) of treated patients, thereby reducing the number of inflammatory cells migrating to the central nervous system (CNS) [9-12].

Limited information is available concerning the effects of fingolimod on different T and B cell subtypes and on the interplay between these lymphocyte populations in the PB of MS patients [13-15]. To understand the longitudinal immunological effects of fingolimod treatment, we investigated the effect of this treatment on B and T cell subtypes and antigen presentation, costimulation and migration molecules expressed on these cells in PB of MS patients in a 12 months follow-up study.

Materials and Methods

Study population
PB was collected from MS patients in both the Orbis Medical Center (Sittard, the Netherlands) and Rehabilitation and MS-center (Overpelt, Belgium). For PB collection in the Orbis Medical Center, written informed consent was obtained from all participants after approval by the Medical ethical Committee Atrium-Orbis-Zuyd (12-N-56). Furthermore, PB was collected by the Rehabilitation and MS-center in Overpelt after written informed consent from all participants and approval by the UZ Leuven and Hasselt University Commissions of Medical Ethics (S54362 and S54363). A total of 123 MS patients were involved in the study, including 47 treatment-naive MS patients, 27 MS patients on interferon-β (IFN-β) treatment (together referred to as controls) and 49 MS patients on fingolimod treatment (0.5 mg/day). All MS patients were diagnosed according to the revised McDonald criteria [16]. Treatment-naive MS patients never received any MS related treatment. PB of the fingolimod-treated group was collected after wash-out of the previous treatment (minimally 2 months) and before the first dose of fingolimod (baseline). MS patients were then followed over time: PB was collected after 1 month (1 m), 3 months (3 m) and every 3 consecutive months of treatment for a period of up to 12 months (6 m, 9 m, 12 m). Clinical non-responders to fingolimod treatment were characterized by an increase in EDSS score, a relapse or a new magnetic resonance imaging (MRI) lesion after a minimum of 3 months of fingolimod treatment and were excluded from the study.

Flow cytometry
PB was collected in heparin-coated tubes (Venosafe plastic tubes, Terumo Europe N.V., Leuven, Belgium) and PB mononuclear cells (PBMC) were isolated using high density centrifugation (Lympholyte; Cedarlane Laboratories, SanBio B.V., Uden, the Netherlands). PBMC (0.5x10⁶ cells) were stained using anti-human CD19 PerCP-Cy5.5 and CD4 APC to discriminate between B and T cells, respectively (BD Biosciences, Erembodegem, Belgium). B cell subpopulations and surface molecules were defined using following anti-human antibodies: IgD APC-Cy7, CD27 PE-Cy7, HLA-DR/DP/DQ (major histocompatibility complex (MHC)-II) FITC, CD80 PE and CD86 PE-CF594 (all from BD Biosciences, Erembodegem, Belgium). Following anti-human monoclonal antibodies were used for T cell analysis: CD45RA APC-H7, CD45RO PE-CF594, CXCR5 Alexa Fluor 488 and PD-1 PE-Cy7 (all from BD Biosciences, Erembodegem, Belgium), CD25 PerCP-Cy5.5 and CD127 PE (E Bioscience, San Diego, USA). Following isotype controls were used: mouse IgG1 PerCP-Cy5.5, IgG1 PE, IgG1 PE-Cy7, IgG2a PE-CF594, IgG2b APC-H7, IgG1 APC, IgG2aX FITC, IgG1k PE-CF594, IgG1 Pe-Cy7, IgG2aX APC-H7 and rat IgG2b Alexa Fluor 488 (all from BD Biosciences, Erembodegem, Belgium). All flow cytometric analyses were performed on a FACS AriaII flow cytometer and analyzed with FACS Diva software (BD Biosciences).

Statistical analysis
Data analysis was performed using Prism software version 5.01 (graphpad) and SAS 9.3 software. Appropriate One-way ANOVA analysis was used with Dunn’s multiple comparison post-hoc test for comparison of treatment controls and baseline fingolimod-treated patients after normality check (Kolmogorov-Smirnov). A mixed model was used for data analysis of treatment follow-up compared to baseline fingolimod. A p-value of <0.05 was considered statistically significant.

Results

Reduction of total PB lymphocyte, B and T cell counts after fingolimod treatment
In total, PB of 49 fingolimod-treated MS patients was collected at different time points up to 12 months of treatment. The cohort of fingolimod-treated MS patients was compared at baseline with 47 treatment-naive and 27 IFN-β treated MS patients (together referred to as controls). Fingolimod-treated MS patients at baseline and controls were comparable in terms of age, gender distribution and median EDSS score (table 1). Furthermore, no significant difference was observed in numbers of total lymphocytes, B cells or T cells (figure 1) between baseline fingolimod treatment and controls. For the MS patients receiving fingolimod treatment, pretreatment (baseline) values were used as reference to assess the effects of treatment. Five of 49 fingolimod-treated MS patients did not finish the study due to side effects caused by the treatment. Seven MS patients were excluded from the study as clinical non-responders, although, no differences in T and B cell subtype proportions between non-responders and responders were found (data not shown).

Total lymphocyte numbers were decreased after 1 month (1 m) of fingolimod treatment compared with baseline and controls for the total duration of the study (12 m) (p<0.001; figure 1). Furthermore, total CD19+ B cell and CD4+ T cell numbers were decreased at 1 m and reached a steady state at 3 m (p<0.001; figure 1). Similar results were observed for the percentage of CD19+ and CD4+ cells within the lymphocyte population (p<0.001; table S1).

Fingolimod affects B cell subtype distribution in the PB of MS patients
During immune responses, B cells produce antibodies after maturation into plasma cells, function as antigen presenting cells, provide costimulation for T cells and play a role in immune memory. In MS, memory B cells and plasma cells may contribute...
Table 1. Study population.

| Agea (range) | Gender | Classificationb | EDSSc (range) |
|-------------|--------|-----------------|---------------|
|             | F/M    | RR             | CP            |
| Total (n = 123) | 44 (17–79) | 90/33 | 92 | 23 | 2.5 (0.0–7.0) |
| Treatment naive (n = 47) | 48 (17–79) | 33/14 | 29 | 12 | 2.5 (0.0–7.0) |
| Interferon (n = 27) | 42 (17–66) | 19/8 | 22 | 5 | 2.5 (1.0–6.5) |
| Fingolimod (n = 49) | 44 (18–69) | 38/11 | 43 | 6 | 2.5 (0.0–6.5) |
| Non-responders (n = 7) | 49 (34–54) | 5/2 | 4 | 3 | 4.0 (1.0–6.5) |
| Drop outs (n = 5) | 41 (32–56) | 5/0 | 5 | 0 | 2.0 (1.5–6.0) |
| 0 m (n = 28) | 43 (18–67) | 21/7 | 25 | 3 | 2.5 (0.0–6.0) |
| 1 m (n = 24) | 41 (18–67) | 18/6 | 22 | 2 | 2.5 (0.0–6.0) |
| 3 m (n = 29) | 43 (18–67) | 22/7 | 26 | 3 | 2.5 (0.0–6.0) |
| 6 m (n = 26) | 43 (18–69) | 20/6 | 24 | 2 | 2.5 (0.0–6.0) |
| 9 m (n = 27) | 45 (18–69) | 23/4 | 24 | 3 | 2.5 (0.0–6.0) |
| 12 m (n = 13) | 45 (29–69) | 11/2 | 12 | 1 | 2.5 (0.0–5.0) |

a. Mean age in years.
b. For 6 treatment-naive patients, MS type was not specified.
c. Median EDSS score; this information was not available for 7 treatment-naive patients and 6 IFN-β-treated patients.

To the pathogenesis by production of autoantibodies and cytokines [17].

Although B cell numbers were reduced in the PB after fingolimod treatment, we investigated the effects of fingolimod treatment on the remaining B cell population in the PB of treated patients. Both non class-switched (CD19+IgD−CD27+) and class-switched memory B cells (CD19+IgD+CD27+) were significantly decreased in the peripheral B cell population from 3 m until end of follow-up (p<0.001; figure 2A, table S1, figure S1). In contrast, the percentage of CD19+IgD−CD27− cells (double negative B cells) was significantly increased within the B cell population at 1 m up to 12 m (p<0.05 at 1 m; p<0.001 at 3–12 m; figure 2A, table S1, figure S1). Naïve B cells (CD19+IgD+CD27+) made up about 50% of the remaining peripheral B cells and the proportion of these cells was increased after 3 m fingolimod until end of follow-up (p<0.03; figure 2A; table S1, figure S1).

Distribution of B cell subtypes at start of fingolimod treatment was the same as in treatment-naive and IFN-β-treated MS patients (table S1). In general, fingolimod treatment caused a decline in memory B cell subpopulations while naïve and double negative B cell proportions were increased in the PB of MS patients.

Change in surface expression of molecules involved in B cell antigen presentation and costimulation under fingolimod treatment

B cells are potent antigen presenting cells via the surface molecule HLA-DR/DP/DQ (MHC-II) and are important to provide costimulation to T cells via the surface molecules CD80 and CD86 [18].

During fingolimod treatment, both the percentage of HLA-DR/DP/DQ, CD80 and CD86 positive cells and the expression of these surface markers on CD19+ B cells was assessed using flow cytometric analysis. The percentage of HLA-DR/DP/DQ+ B cells (data not shown) and the expression of HLA-DR/DP/DQ (MFI) on B cells was significantly decreased after 3 m and 1 m of fingolimod treatment, respectively, in comparison with baseline (p<0.05; figure 3A; table S2). Fingolimod treatment resulted in an
increased expression of both CD86 (after 1 m) and CD80 (after 3 m and 12 m) on B cells (MFI) compared with baseline ($p < 0.05$; figure 3B and C; table S2). The percentages of CD80$^+$ and CD86$^+$ B cells remained stable during the follow-up period (table S2). Expression of antigen presentation and costimulation markers on B cells was comparable between baseline fingolimod and controls (table S2). Thus, the expression of HLA-DR/DP/DQ on PB B cells was decreased (both percentage of positive cells and MFI), while the expression of the costimulation molecules CD80 and CD86 (MFI) was increased during fingolimod treatment in MS patients.

**Fingolimod affects conventional and regulatory T cell subtype distribution in the PB of MS patients**

Conventional T cells (Tconv, CD4$^+$CD25$^-$CD127$^+$) are considered to be main players in maintaining a normal immune response and exert autoreactivity in autoimmune diseases like MS [1]. Regulatory T cells (Treg, CD4$^+$CD25$^{hi}$CD127$^{lo}$) are essential for immune homeostasis and were shown to be functionally impaired in MS pathogenesis [1].

The longitudinal effects of fingolimod treatment on different CD4$^+$ T cell subtypes including naive (CD45RA$^+$CD45RO$^-$), memory (CD45RA$^-$CD45RO$^+$) and transitional (CD45RA$^+$CD45RO$^+$) cells within both Tconv and Treg populations were assessed using flow cytometry. For the Tconv population, the proportion of naive cells was decreased in fingolimod-treated patients at all timepoints measured, when compared with baseline ($p < 0.001$; figure 2B; table S1, figure S2). In contrast, a significant increase in the percentage of memory Tconv was observed after 1 m until 12 m in comparison with baseline ($p < 0.001$; figure 2B; table S1, figure S2).

The percentage of naive cells within the Treg subtypes displayed a significant decrease after 1 m, 3 m and 6 m ($p < 0.05$; figure 2B; table S1, figure S2), while a significant increase was observed in the proportion of memory Tregs after 1 m until 9 m ($p < 0.001$), as observed for the Tconv population. Interestingly, the transitional T cells (CD45RA$^+$CD45RO$^+$), both in the regulatory and conventional T cell population, remained stable throughout the 12 month follow-up period. Of note, baseline levels of the fingolimod-treated groups differed significantly compared with treatment-naive patients for Tconv and Treg ($p < 0.05$; table S1). Similar changes were observed when comparing IFN-$

---

**Figure 2. Proportional B cell and T cell subtype changes in MS patients during fingolimod treatment.** (A) CD19$^+$ B cell subtype proportion and (B) CD4$^+$ T cell subtype proportion within the PB of treatment-naive, IFN-$

---

**Table S1.**

| Time | B Cells | T Cells |
|------|---------|---------|
| Start | 23      | TransTconv |
| 1m    | 24      | 24.0     |
| 3m    | 25      | 22.9     |
| 6m    | 25      | 24.1     |
| 9m    | 27      | 22.5     |
| 12m   | 12      | 20.3     |

---

**Figure S2.** Proportional B cell subtype changes in MS patients during fingolimod treatment. (A) CD19$^+$ B cell subtype proportion and (B) CD4$^+$ T cell subtype proportion within the PB of treatment-naive, IFN-$

---

**Note:**

- Baseline levels of the fingolimod-treated groups differed significantly compared with treatment-naive patients for Tconv and Treg ($p < 0.05$; table S1).
- Similar changes were observed when comparing IFN-$

---

**Legend:**

- **A:** CD19$^+$ B cell subtype proportions
- **B:** CD4$^+$ T cell subtype proportions

---

**References:**

1. [1]
PD-1 expression increases on circulating follicular helper T cells during fingolimod treatment

Circulating CXCR5⁺ PD-1⁺ follicular helper T cells (T_{FH}) have the capacity to recirculate in secondary lymphoid organs where they can interact with B cells and influence the germinal center response [19].

The percentage of T_{FH} (CD4⁺CD25⁻CD127⁺CXCR5⁺PD-1⁺) remained stable within the CD4⁺ population during fingolimod treatment (figure 4A, table S1).

To assess the effect of fingolimod on the expression of molecules involved in cell migration towards the germinal center and molecules involved in the functionality of the germinal center response, CXCR5 and PD-1 expression levels were determined on
TFH cells [19–22]. While the expression of CXCR5 on T_{FH} did not change in fingolimod-treated MS patients (figure 4B; table S2), a significant increase of the expression of PD-1 on PB T_{FH} cells was observed during follow-up (p<0.05; figure 4C; table S2). These results show that the frequency of circulating T_{FH} cells that egress from the lymph nodes was not affected by treatment with fingolimod, while expression of PD-1 on these T_{FH} cells in the PB of MS patients was increased.

**Discussion**

In this study, we elucidate the effects of fingolimod, approved as therapy for RR-MS, on different B and T cell subtypes and expression of surface molecules involved in antigen presentation,
costimulation and migration during a 12 month follow-up study. Under fingolimod treatment, the B cell subtype distribution changed, resulting in a decreased proportion of memory B cells and an increased proportion of naive and double negative B cells in the PB. In contrast, the proportions of T cell subtypes changed towards less naive Tconv and naive Treg in the PB, while the proportions of memory Tconv and memory Treg increased. Finally, expression of CD86 and CD80 costimulatory molecules on B cells as well as the expression of PD-1 on circulating TFH were changed during fingolimod treatment.

We confirmed, as shown by others, that fingolimod reduced total lymphocyte, B and T cell numbers in the PB of MS patients [12,23,24]. For a comprehensive overview of the effects of fingolimod treatment on different cell types, we refer to the review of Brinkmann et al. [9].

The beneficial effects of fingolimod as MS treatment with minimal side effects could be attributed to different mechanisms of action. Fingolimod could entrap lymphocyte subtypes involved in MS pathogenesis in the lymph nodes by directly influencing migration of these lymphocytes from the lymph nodes into the circulation. As already reported by others, we show a decrease in peripheral memory B cells (both non-class-switched and class-switched) while the naive B cell proportion increases [14,15]. Although we do not report functional data, this finding could contribute to the beneficial effect of fingolimod treatment in MS patients. Memory B cells are largely implicated in MS pathogenesis as they are able to produce specific (auto)antibodies and are able to migrate to the CNS to enhance the ongoing immune response [3,17,25]. Entrapment of memory B cells in the lymph nodes could be a direct consequence of fingolimod’s effect on S1PR1 signaling [14]. Additional proof of memory B cell entrapment in the lymph nodes comes from mice studies that showed a decrease in high-affinity class-switched antibodies by fingolimod, produced by memory B cells in the serum [26]. Furthermore, vaccination studies in fingolimod-treated healthy volunteers have demonstrated a mild to moderate decrease in immunoglobulin (Ig)G and IgM antibody levels towards some antigens [27].

B cells are important antigen presenting cells and recent evidence from mice studies has indicated that fingolimod can influence antigen handling [28–30]. In our study, B cell expression of the antigen presentation marker HLA-DR/DP/DQ and the percentage of HLA-DR/DP/DkDq B cells was decreased in the PB during fingolimod treatment, which could be beneficial for MS pathogenesis since less antigen presentation occurs. However, this effect could also be attributed to a change in B cell subtype proportions in the PB.

Next to changes in B cell proportions, fingolimod treatment led to a decrease in the proportion of peripheral naive Tconv and an increase in the memory Tconv. Our results are in agreement with previous studies showing that effector memory T cells (TEM), lacking expression of C-C chemokine receptor type 7 (CCR7), were increased in the PB of fingolimod-treated MS patients [31]. It is thought that these circulating TEM have a suppressor function and downregulate the autoimmune response [10].

Furthermore, the homeostasis and function of Treg is disturbed in MS [32,33]. In addition to the previously described increase in percentage of Tregs in the PB under fingolimod treatment, we show that the increase in Tregs is mostly attributed to an expansion in the memory population while a decrease in naive Treg cells was observed [13,34]. Of note, an increase in memory Tregs could be responsible for recovery of Treg suppressive activity under fingolimod treatment as previously illustrated by our group for patients with SPMS [33]. It was already speculated that treatment with fingolimod works by both sequestering autoreactive B and T cells in the secondary lymphoid organs and by enhancing the functionality and frequency of circulating Treg [35].

As circulating T_{FH} are important for a normal germinal center response [36], we investigated whether these cells are affected by fingolimod treatment in the PB of MS patients and found that fingolimod treatment did not change the percentage of circulating T_{FH} cells. Recent evidence indicated that circulating T_{FH} cells consist of a CCR7+PD-1hi subpopulation with an effector phenotype. Therefore these cells could be less responsive to fingolimod as observed for memory Treg and Tconv cells [37].

Although fingolimod causes entrapment of lymphocytes in the lymph nodes, expression of surface molecules involved in costimulation was increased, which could point to a gain of functionality of the remaining circulating lymphocyte subtypes, although functional assessment is needed using both in vitro and animal studies to confirm this argument. During fingolimod treatment expression of CD86 and CD80 costimulatory molecules on B cells was increased and furthermore, an increase in PD-1 expression on T_{FH} cells was observed. The percentage of CD69+ B cells was increased as well during fingolimod treatment, which could be attributed to a change in B cell subtype distribution. Expression of CXCR5 on T_{FH} cells was unchanged during treatment, indicative of normal migration of these cells from the marginal zone to the follicles in the lymph nodes. Considering the beneficial clinical effects of fingolimod, we hypothesize that this increase in B and T cell costimulation and no change in migration capacity is a rescue mechanism to augment functionality of the remaining B and T cells, thereby warranting normal immunity. An additional proof of normal immune function is that vaccine specific production of IgM and IgG towards influenza A and B in fingolimod-treated individuals was not impaired when compared to levels in healthy controls [38].

Due to technical limitations and low cell numbers available for analysis, CD8+ and natural killer (NK) cells were not assessed. Further limitations of the study are the lack of functional data, although we provide evidence that during fingolimod treatment expression of functionally relevant markers on the remaining B and T cell subtypes in the peripheral blood of MS patients can change.

To conclude, this study shows that fingolimod induces compositional changes of B and T cell subtypes that are potentially implicated in MS pathogenesis and may explain the therapeutic efficacy of the treatment. While altered surface expression of functional molecules on B and T cells during fingolimod treatment suggests that normal immune function may prevail, functional evidence for this has still to be provided during future research. With this descriptive study we provide additional longitudinal immunological proof for the diverse mechanisms of action of fingolimod in MS patients.

Supporting Information

Figure S1 Proportional changes of B cell subtypes during fingolimod treatment in MS patients. Proportional composition of (A) naive B cells, (B) non class-switched memory B cells, (C) class-switched memory B cells and (D) double negative B cells within the CD19+ B cell population of treatment-naïve, IFN-β and fingolimod-treated MS patients. (TIF)

Figure S2 Compositional changes of T cell subtypes during fingolimod treatment in MS patients. Proportional changes of (A) naïve conventional T cells, (B) memory conven-
tional T cells, (C) transitional conventional T cells, (D) naive regulatory T cells, (E) memory regulatory T cells and (F) transitional regulatory T cells. Changes are depicted as percentage within the CD4+ T cell population and measured in treatment-naive, IFN-β and fingolimid-treated MS patients. (TH)

Table S1 Mean percentages of different B and T cell subtypes. (DOCX)

Table S2 Mean fluorescence intensity and percentage positive cells of different surface markers on B and T cells. (DOCX)

References
1. Broux B, Stinissen P, Hellings N (2013) Which immune cells matter? The immunopathogenesis of multiple sclerosis. Crit Rev Immunol 33: 283–306.
2. Fraussen J, Vrolix K, Martinez-Martin P, Losen M, De Baets MH, et al. (2009) B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev 8: 654–630.
3. Palanichamy A, Apelman L, Kuo TC, Sirota M, Wang S, et al. (2014) Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 6: 240ra106.
4. Moeser B, Loetscher P (2001) Lymphocyte traffic control by chemokines. Nat Immunol 2: 125–129.
5. Cohen JA, Barkhof F, Coni G, Hartung HP, Khatri BO, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
6. Coni G, O’Connor P, Montalban X, Antel J, Radue EW, et al. (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16: 197–207.
7. Kappos L, Radue EW, O’Connor P, Polman C, Hobléld R, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 397–407.
8. O’Connor P, Coni G, Montalban X, Antel J, Radue EW, et al. (2009) Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72: 73–79.
9. Brinkmann V, Billich A, Baumrucker T, Heining P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 412–423.
10. Pelletier D, Hafer DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366: 339–347.
11. von Wenchert H, Zimmermann K, Kleuer B (2006) The role of the lymphosphospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp (Warsz) 54: 239–251.
12. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kumpfel T, et al. (2011) CLREL analysis of CD8 T cells of multiple sclerosis patients. J Neuroimmune Pharmacol. 6: 197–207.
13. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al. (2008) Differential effects of fingolimod (FTY720) on immune cell subsets in the CSF and blood of patients with MS. Neurology 76: 1214–1221.
14. Sato DK, Nakamura M, Matsuo K, Chihara N, Miyake S, Sato W, et al. (2014) Distinctive effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler.
15. Miyazaki Y, Niino M, Fukazawa T, Takahashi E, Nonaka T, et al. (2014) Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clin Immunol 151: 127–135.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ’McDonald Criteria’. Ann Neurol 58: 840–846.
17. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, et al. (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178: 6092–6099.
18. von Budingen HC, Bar-Or A, Amvl S (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 23: 713–720.
19. Craft JE (2012) Folicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 8: 337–347.
20. Weinstein JS, Hernandez SG, Craft J (2012) T cells that promote B-cell maturation in systemic autoimmunity. Immunol Rev 247: 160–171.
21. Linterman MA, Liston A, Vinuesa CG (2012) T-follicular helper cell differentiation and the co-option of this pathway by non-helper cells. Immunol Rev 247: 143–159.
22. Chung Y, Tanaka S, Chu F, Nuralev RI, Martinez GJ, et al. (2011) Follicular regulatory T cells expressing Foxp3 and CD6 suppress germinal center reactions. Nat Med 17: 983–988.
23. Mehling, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al. (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71: 1261–1267.
24. Mehling, Lindsberg R, Raufl F, Kuhle J, Hess C, et al. (2010) Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 73: 803–410.
25. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, et al. (1990) Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102: 1045–1050.
26. Han S, Zhang X, Wang G, Guan H, Garcia G, et al. (2004) FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 104: 4129–4133.
27. Boulton C, Meier K, David QJ, Schmoeker R (2012) Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. J Clin Pharmacol 52: 1879–1890.
28. Vora KA, Nichols E, Porter G, Cui Y, Keesha CA, et al. (2005) Sphingosine-1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement. J Leukoc Biol 78: 471–480.
29. Canamoglu, Zachariah MA, Lam OM, Foss FW Jr, Cyster JG (2008) Folicular shunting of marginal zone B cells facilitates antigen transport. Nat Immunol 9: 54–62.
30. Canamoglu G, Matloobian M, Lesnicky MJ, Xu Y, Low C, et al. (2004) Sphingosine-1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 5: 713–720.
31. McLaughlin, Johnson TA, Kappos L, Antel J, Bar-Or A (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76: S20–27.
32. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al. (2008) Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79–89.
33. Venken K, Hellings N, Lihlau R, Stinissen P (2010) Disturbed regulatory T cell homostasis in multiple sclerosis. Trends Mol Med 16: 58–68.
34. Serpero LD, Filaci G, Parodi A, Battaglia F, Kalfi F, et al. (2013) Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. J Neuroimmun Pharmacol.
35. Zhou HJ, Wang H, Shi GH, Wang XH, Shen ZJ, et al. (2009) Immunomodulatory drug FTY720 induces regulatory CD4(+)(CD25(+)) T cells in vitro. Clin Exp Immunol 157: 40–47.
36. Teller J, Nutt SL (2013) The unique features of follicular T cell subsets. Cell Mol Life Sci 70: 4711–4710.
37. He J, Tsai LM, Leong YA, Hu X, Ma CS, et al. (2013) Circulating precursor CCR7(lo)PD-1(hi) CXCR3(+)/CD4(+) T cells indicate Th cell activity and promote antibody responses upon antigen reexposure. Immunol 39: 779–790.
38. Mehling M, Hibbert P, Fritz S, Danovic B, Eichin D, et al. (2011) Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 69: 408–413.

Acknowledgments
The authors thank Marjan Vanheusden (Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium) for technical support; Many thanks to Inga Rutten and Kim Uleniers (Hasselt University, Biomedical Research Institute and Ulimit) for helping with patient sample collection; MS research coordination, MS rehabilitation center (Overpelt), Bertrine Timmermans, Ingrid Mevissen and all MS nurses at Orbis Medical Center (Sittard) for patient recruitment and sample collection.

Author Contributions
Conceived and designed the experiments: NC TD BB JF NH VS. Performed the experiments: NC TD BB. Analyzed the data: NC TD. Contributed reagents/materials/analysis tools: RH BVW. Wrote the paper: NC TD BB JF BBW RH PS NH VS.